

## CORRECTION

# Correction: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Gordon C Wishart<sup>\*1,7</sup>, Elizabeth M Azzato<sup>2,3\*</sup>, David C Greenberg<sup>4</sup>, Jem Rashbass<sup>4</sup>, Olive Kearins<sup>5</sup>, Gill Lawrence<sup>5</sup>, Carlos Caldas<sup>1,6,7</sup> and Paul DP Pharoah<sup>2</sup>

See related research by Wishart *et al.*, <http://breast-cancer-research.com/content/12/1/R1>

Following the publication of our article [1] we noticed an error in Table 1 relating to the number of patients who received adjuvant therapy. The correct table is given here (Table 1).

#### Author details

<sup>1</sup>Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK

<sup>2</sup>Strangeways Research Laboratory, Department of Oncology, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK

<sup>3</sup>Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA

<sup>4</sup>Eastern Cancer Registration and Information Centre (ECRIC), Unit C, Magog Court, Shelford Bottom, Hinton Way, Cambridge CB22 3AD, UK

<sup>5</sup>West Midlands Cancer Intelligence Unit, Public Health Building, The University of Birmingham, Birmingham, B15 2TT, UK

<sup>6</sup>Department of Oncology, University of Cambridge, and Functional Breast Cancer Genomics Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka-Shing Centre, Robinson Way, Cambridge CB2 0RE, UK

<sup>7</sup>National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK

Published: 1 March 2010

#### Reference

1. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, Caldas C, Pharoah PD: **PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.** *Breast Cancer Res* 2010, **12**:R1.

doi:10.1186/bcr2480

**Cite this article as:** Wishart GC, *et al.*: Correction: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. *Breast Cancer Research* 2010, **12**:401.

\*Correspondence: [gordon.wishart@addenbrookes.nhs.uk](mailto:gordon.wishart@addenbrookes.nhs.uk)  
Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK  
Full list of author information is available at the end of the article

**Table 1. Patient characteristics for model development (ECRIC) and validation (WMCIU) cohorts**

	ECRIC		WMCIU	
Total Number of Subjects	5,694		5,468	
Total time at risk (years)	31,904		25,917	
Median follow-up (years)*	5.65	(0.04-8.00) <sup>†</sup>	4.85	(0.07-8.00) <sup>†</sup>
Number of breast cancer deaths	737		668	
Number of other deaths	338		287	
Annual breast cancer mortality rate	0.023	(0.021-0.025) <sup>‡</sup>	0.026	(0.024-0.028) <sup>‡</sup>
5-year breast cancer survival rate	0.89	(0.88-0.90) <sup>‡</sup>	0.88	(0.87-0.89) <sup>‡</sup>
Median age at diagnosis, years	58	(23-95) <sup>†</sup>	58	(22-93) <sup>†</sup>
	Number	%	Number	%
Age, years				
<35	111	2	108	2
35-49	1,172	21	1,195	22
50-64	2,630	46	2,393	44
65-74	1,124	20	1,101	20
75+	657	12	671	12
Nodal status				
0	3,532	62	3,184	58
1	741	13	746	14
2-4	806	14	792	14
5-9	380	7	451	8
10+	235	4	295	5
Tumour size, mm				
<10	625	11	485	9
10-19	2,310	41	2,136	39
20-29	1,627	29	1,566	29
30-49	845	15	923	17
50+	287	5	358	7
Grade				
I	1,005	18	1,017	19
II	2,927	51	2,442	45
III	1,762	31	2,009	37
ER Status				
ER negative	991	17	1,116	20
ER positive	4,703	83	4,352	80
Adjuvant therapy				
None	643	11	1,520	28
Chemotherapy only	783	14	1,542	28
Endocrine therapy	3,146	55	1,827	33
Combined chemoendocrine	1,122	20	579	11
Screen detected				
Yes	1,621	28	1,256	23
No	4,073	72	4,212	77

\*Follow-up censored at 8 years

<sup>†</sup>Range of variable

<sup>‡</sup>95 CI